Oral CorticoSteroid sparing with biologics in severe asthma: A remark of the Severe Asthma Network in Italy (SANI): World Allergy Organization Journal

G.W. Canonica; F. Blasi; P. Paggiaro; G. Senna; G. Passalacqua; A. Spanevello; S. Aliberti; D. Bagnasco; M. Bonavia; M. Bonini; L. Brussino; C. Bucca; M.F. Caiaffa; C. Calabrese; G. Camiciottoli; M. Caminati; G.E. Carpagnano; C. Caruso; S. Centanni; M.E. Conte; A.G. Corsico; L. Cosmi; M.T. Costantino; N. Crimi; S. D'Alò; M. D'Amato; S. Del Giacco; A. Farsi; E. Favero; M.P. Foschino Barbaro; G. Guarnieri; G. Guida; M. Latorre; S. Lo Cicero; C. Lombardi; L. Macchia; F. Mazza; F. Menzella; M. Milanese; M. Montagni; P. Montuschi; E. Nucera; R. Parente; V. Patella; G. Pelaia; L. Pini; F. Puggioni; L. Ricciardi; F.L.M. Ricciardolo; L. Richeldi; E. Ridolo; G. Rolla; P. Santus; N. Scichilone; G. Spadaro; A. Vianello; V. Viviano; M.R. Yacoub; M.C. Zappa; E. Heffler; SANI (Severe Asthma Network Italy)

doi:10.1016/j.waojou.2020.100464

Oral CorticoSteroid sparing with biologics in severe asthma: A remark of the Severe Asthma Network in Italy (SANI): World Allergy Organization Journal

G.W. Canonica, F. Blasi, P. Paggiaro, G. Senna, G. Passalacqua, A. Spanevello, S. Aliberti, D. Bagnasco, M. Bonavia, M. Bonini, L. Brussino, C. Bucca, M.F. Caiaffa, C. Calabrese, G. Camiciottoli, M. Caminati, G.E. Carpagnano, C. Caruso, S. Centanni, M.E. ConteA.G. Corsico, L. Cosmi, M.T. Costantino, N. Crimi, S. D'Alò, M. D'Amato, S. Del Giacco, A. Farsi, E. Favero, M.P. Foschino Barbaro, G. Guarnieri, G. Guida, M. Latorre, S. Lo Cicero, C. Lombardi, L. Macchia, F. Mazza, F. Menzella, M. Milanese, M. Montagni, P. Montuschi, E. Nucera, R. Parente, V. Patella, G. Pelaia, L. Pini, F. Puggioni, L. Ricciardi, F.L.M. Ricciardolo, L. Richeldi, E. Ridolo, G. Rolla, P. Santus, N. Scichilone, G. Spadaro, A. Vianello, V. Viviano, M.R. Yacoub, M.C. Zappa, E. Heffler, SANI (Severe Asthma Network Italy)

Research output: Contribution to journal › Review article › peer-review

Abstract

According to the data derived from several national and international registries, including SANI (Severe Asthma Network Italy), and considering the strong impact that frequent or regular use of oral corticosteroid has on quality of life (QoL) of severe asthmatics, as well as on the costs for managing corticosteroid-related diseases, oral corticosteroid sparing up to withdrawal should be considered a primary outcome in the management of severe asthma. New biologics have clearly demonstrated that this effect is possible, with concomitant reduction in the rate of exacerbations and in symptom control. Then, there is no reason for using so frequently oral corticosteroid before having explored all alternatives currently available for a large part of severe asthmatics.

Original language	English
Article number	100464
Pages (from-to)	100464
Journal	World Allergy Organ. J.
Volume	13
Issue number	10
DOIs	https://doi.org/10.1016/j.waojou.2020.100464
Publication status	Published - Oct 2020

Access to Document

10.1016/j.waojou.2020.100464

https://www.scopus.com/inward/record.uri?eid=2-s2.0-85091219259&doi=10.1016%2fj.waojou.2020.100464&partnerID=40&md5=ed8165eca34dcc53d11dcbfebb6f8783

Cite this

Canonica, G. W., Blasi, F., Paggiaro, P., Senna, G., Passalacqua, G., Spanevello, A., Aliberti, S., Bagnasco, D., Bonavia, M., Bonini, M., Brussino, L., Bucca, C., Caiaffa, M. F., Calabrese, C., Camiciottoli, G., Caminati, M., Carpagnano, G. E., Caruso, C., Centanni, S., ... Italy), SANI. (2020). Oral CorticoSteroid sparing with biologics in severe asthma: A remark of the Severe Asthma Network in Italy (SANI): World Allergy Organization Journal. World Allergy Organ. J., 13(10), 100464. [100464]. https://doi.org/10.1016/j.waojou.2020.100464

Canonica, GW , Blasi, F, Paggiaro, P, Senna, G, Passalacqua, G, Spanevello, A , Aliberti, S, Bagnasco, D, Bonavia, M, Bonini, M, Brussino, L, Bucca, C, Caiaffa, MF, Calabrese, C, Camiciottoli, G, Caminati, M, Carpagnano, GE, Caruso, C, Centanni, S, Conte, ME, Corsico, AG, Cosmi, L, Costantino, MT, Crimi, N, D'Alò, S, D'Amato, M, Del Giacco, S, Farsi, A, Favero, E, Foschino Barbaro, MP, Guarnieri, G, Guida, G, Latorre, M, Lo Cicero, S , Lombardi, C, Macchia, L, Mazza, F, Menzella, F, Milanese, M, Montagni, M, Montuschi, P, Nucera, E, Parente, R, Patella, V, Pelaia, G, Pini, L, Puggioni, F, Ricciardi, L, Ricciardolo, FLM, Richeldi, L, Ridolo, E, Rolla, G, Santus, P, Scichilone, N, Spadaro, G, Vianello, A, Viviano, V, Yacoub, MR, Zappa, MC, Heffler, E & Italy), SANI 2020, 'Oral CorticoSteroid sparing with biologics in severe asthma: A remark of the Severe Asthma Network in Italy (SANI): World Allergy Organization Journal', World Allergy Organ. J., vol. 13, no. 10, 100464, pp. 100464. https://doi.org/10.1016/j.waojou.2020.100464

@article{5075b60055d14954948feddc598a6493,

title = "Oral CorticoSteroid sparing with biologics in severe asthma: A remark of the Severe Asthma Network in Italy (SANI): World Allergy Organization Journal",

abstract = "According to the data derived from several national and international registries, including SANI (Severe Asthma Network Italy), and considering the strong impact that frequent or regular use of oral corticosteroid has on quality of life (QoL) of severe asthmatics, as well as on the costs for managing corticosteroid-related diseases, oral corticosteroid sparing up to withdrawal should be considered a primary outcome in the management of severe asthma. New biologics have clearly demonstrated that this effect is possible, with concomitant reduction in the rate of exacerbations and in symptom control. Then, there is no reason for using so frequently oral corticosteroid before having explored all alternatives currently available for a large part of severe asthmatics.",

author = "G.W. Canonica and F. Blasi and P. Paggiaro and G. Senna and G. Passalacqua and A. Spanevello and S. Aliberti and D. Bagnasco and M. Bonavia and M. Bonini and L. Brussino and C. Bucca and M.F. Caiaffa and C. Calabrese and G. Camiciottoli and M. Caminati and G.E. Carpagnano and C. Caruso and S. Centanni and M.E. Conte and A.G. Corsico and L. Cosmi and M.T. Costantino and N. Crimi and S. D'Al{\`o} and M. D'Amato and {Del Giacco}, S. and A. Farsi and E. Favero and {Foschino Barbaro}, M.P. and G. Guarnieri and G. Guida and M. Latorre and {Lo Cicero}, S. and C. Lombardi and L. Macchia and F. Mazza and F. Menzella and M. Milanese and M. Montagni and P. Montuschi and E. Nucera and R. Parente and V. Patella and G. Pelaia and L. Pini and F. Puggioni and L. Ricciardi and F.L.M. Ricciardolo and L. Richeldi and E. Ridolo and G. Rolla and P. Santus and N. Scichilone and G. Spadaro and A. Vianello and V. Viviano and M.R. Yacoub and M.C. Zappa and E. Heffler and Italy), {SANI (Severe Asthma Network}",

note = "Export Date: 28 September 2020 Correspondence Address: Heffler, E.; Personalized Medicine, Asthma and Allergy, Istituto Clinico Humanitas, Via Alessandro Manzoni 56, Italy; email: heffler.enrico@gmail.com",

year = "2020",

month = oct,

doi = "10.1016/j.waojou.2020.100464",

language = "English",

volume = "13",

pages = "100464",

journal = "World Allergy Organ. J.",

issn = "1939-4551",

publisher = "Elsevier Inc.",

number = "10",

}

TY - JOUR

T1 - Oral CorticoSteroid sparing with biologics in severe asthma: A remark of the Severe Asthma Network in Italy (SANI)

T2 - World Allergy Organization Journal

AU - Canonica, G.W.

AU - Blasi, F.

AU - Paggiaro, P.

AU - Senna, G.

AU - Passalacqua, G.

AU - Spanevello, A.

AU - Aliberti, S.

AU - Bagnasco, D.

AU - Bonavia, M.

AU - Bonini, M.

AU - Brussino, L.

AU - Bucca, C.

AU - Caiaffa, M.F.

AU - Calabrese, C.

AU - Camiciottoli, G.

AU - Caminati, M.

AU - Carpagnano, G.E.

AU - Caruso, C.

AU - Centanni, S.

AU - Conte, M.E.

AU - Corsico, A.G.

AU - Cosmi, L.

AU - Costantino, M.T.

AU - Crimi, N.

AU - D'Alò, S.

AU - D'Amato, M.

AU - Del Giacco, S.

AU - Farsi, A.

AU - Favero, E.

AU - Foschino Barbaro, M.P.

AU - Guarnieri, G.

AU - Guida, G.

AU - Latorre, M.

AU - Lo Cicero, S.

AU - Lombardi, C.

AU - Macchia, L.

AU - Mazza, F.

AU - Menzella, F.

AU - Milanese, M.

AU - Montagni, M.

AU - Montuschi, P.

AU - Nucera, E.

AU - Parente, R.

AU - Patella, V.

AU - Pelaia, G.

AU - Pini, L.

AU - Puggioni, F.

AU - Ricciardi, L.

AU - Ricciardolo, F.L.M.

AU - Richeldi, L.

AU - Ridolo, E.

AU - Rolla, G.

AU - Santus, P.

AU - Scichilone, N.

AU - Spadaro, G.

AU - Vianello, A.

AU - Viviano, V.

AU - Yacoub, M.R.

AU - Zappa, M.C.

AU - Heffler, E.

AU - Italy), SANI (Severe Asthma Network

N1 - Export Date: 28 September 2020 Correspondence Address: Heffler, E.; Personalized Medicine, Asthma and Allergy, Istituto Clinico Humanitas, Via Alessandro Manzoni 56, Italy; email: heffler.enrico@gmail.com

PY - 2020/10

Y1 - 2020/10

N2 - According to the data derived from several national and international registries, including SANI (Severe Asthma Network Italy), and considering the strong impact that frequent or regular use of oral corticosteroid has on quality of life (QoL) of severe asthmatics, as well as on the costs for managing corticosteroid-related diseases, oral corticosteroid sparing up to withdrawal should be considered a primary outcome in the management of severe asthma. New biologics have clearly demonstrated that this effect is possible, with concomitant reduction in the rate of exacerbations and in symptom control. Then, there is no reason for using so frequently oral corticosteroid before having explored all alternatives currently available for a large part of severe asthmatics.

AB - According to the data derived from several national and international registries, including SANI (Severe Asthma Network Italy), and considering the strong impact that frequent or regular use of oral corticosteroid has on quality of life (QoL) of severe asthmatics, as well as on the costs for managing corticosteroid-related diseases, oral corticosteroid sparing up to withdrawal should be considered a primary outcome in the management of severe asthma. New biologics have clearly demonstrated that this effect is possible, with concomitant reduction in the rate of exacerbations and in symptom control. Then, there is no reason for using so frequently oral corticosteroid before having explored all alternatives currently available for a large part of severe asthmatics.

UR - http://www.scopus.com/inward/record.url?scp=85091219259&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85091219259&partnerID=8YFLogxK

U2 - 10.1016/j.waojou.2020.100464

DO - 10.1016/j.waojou.2020.100464

M3 - Review article

C2 - 32999699

SN - 1939-4551

VL - 13

SP - 100464

JO - World Allergy Organ. J.

JF - World Allergy Organ. J.

IS - 10

M1 - 100464

ER -

Oral CorticoSteroid sparing with biologics in severe asthma: A remark of the Severe Asthma Network in Italy (SANI): World Allergy Organization Journal

Abstract

Access to Document

Other files and links

Fingerprint

Cite this